ArticleAmerican journal of clinical and experimental immunology2026
Association of early-pregnancy platelet-to-high-density lipoprotein cholesterol ratio with preeclampsia: a retrospective cohort study.
Article in American journal of clinical and experimental immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPreeclampsia (PE) is a major cause of poor maternal and perinatal outcomes. While a number of biophysical and biochemical markers have been explored for early prediction, there is a need for low-cost accessible markers. The platelet-to-high-density lipoprotein cholesterol ratio (PHR) might reflect the combined effects of impaired platelet function, inflammatory thrombosis and reduced protection against vascular injury.
methodsThis retrospective cohort included 11,618 pregnancies assessed in early pregnancy. PHR, calculated from platelet count and high-density lipoprotein cholesterol, was analyzed per 10-unit increment. Logistic regression assessed associations with PE, subgroup analyses examined major phenotypes, and receiver operating characteristic analyses compared individual discrimination with mean arterial pressure multiples of the median (MAP MoM) and placental growth factor multiples of the median (PlGF MoM) values.
resultsAmong 11,618 pregnancies, 468 women (4.03%) developed PE. Median PHR per 10 was lower among women who developed PE than among those who did not (15.07 [IQR, 11.93-18.24] vs. 19.05 [IQR, 16.82-21.75]; P<0.001). In multivariable analyses controlling for maternal age, body mass index before pregnancy, parity, type of gestation, and conception by in vitro fertilization, every 10-point rise in PHR was linked to a reduced likelihood of PE (adjusted odds ratio, 0.69; 95% CI, 0.67-0.72; P<0.001). PHR values were significantly decreased in early-onset, preterm, and late-onset PE compared with pregnancies without PE (all P<0.01), but did not differ significantly across these three subtypes. Among participants with available Fetal Medicine Foundation (FMF) screening data, the AUCs were 0.732 (95% CI, 0.693-0.771) for PHR, 0.702 (95% CI, 0.669-0.738) for MAP MoM, and 0.606 (95% CI, 0.570-0.638) for PlGF MoM.
conclusionLower early-pregnancy PHR was independently associated with subsequent PE. PHR had the highest AUC point estimate among the three individual biomarkers evaluated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.